Clinical Study

Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases

Table 3

Number of WBCs and levels of protein in the CSF in our study.

PatientWBC (×106/l)Protein (g/l)
FirstSecondThirdFourthFirstSecondThirdFourth

AD-0010.3818120.240.280.270.26
AD-0022241990.230.300.350.29
ADEM-00301100.540.580.691.10
ES-00421215180.930.871.250.97
HSP-005124780.210.220.180.29
ICH-00639411220.250.250.420.46
IS-0076620260.660.640.810.62
IS-0085151242300.520.580.870.99
IS-009121230.460.580.530.51
IS-01016830.590.630.560.41
IS-0113119100.540.500.490.53
IS-01246150.750.750.790.81
IS-01323536250.260.350.300.31
IS-014999120.570.520.590.66
IS-01521333450.550.701.260.85
IS-0160276.50.440.530.740.58
IS-017376110.691.040.401.35
IS-018510770.490.560.631.48
ML-019212/0.520.350.26/
ML-02012220.250.310.430.49
ML-021121619720.250.290.290.58
MND-0221131170.480.500.440.44
MND-02311211180.600.760.540.46
MND-0240831280.400.290.410.49
MND-025215//0.350.48//
MND-026210520.690.850.750.71
MS-02722400.310.340.370.35
MSA-028245180.260.280.250.34
MSA-02911122061550.240.550.420.50
SCA-03021317230.260.220.290.31
SCA-03131923810.210.230.240.26
SCI-03262649490.640.590.590.99
SCI-033152801191120.801.190.980.95
SCI-034//016.4//0.550.49
SCI-035434110.340.330.320.20
TBI-0362.672134.30.240.220.280.23
TP-037361380.900.770.740.94

Abbreviations: AD, Alzheimer’s disease; ADEM, acute disseminated encephalomyelitis; ES, encephalopathy syndrome; HSP, hereditary spastic paraplegia; ICH, intracerebral haemorrhage; IS, ischaemia stroke; ML, myelitis; MND, motor neuron disease; MS, multiple sclerosis; MSA, multiple system atrophy; PBP, progressive bulbar paralysis; SCA, spinocerebellar ataxia; SCI, spinal cord injury; TBI, traumatic brain injury; TP, thermoplegia.